Review article: Medical guidelines

Management of dupilumab-associated ocular surface diseases in atopic dermatitis patients

Publication Date: 20.08.2021
Swiss Med Wkly. 2021;151:w30020

Yan Guex-Crosiera, Julie Di-Luccab, Peter Häusermannc, Emmanuel Laffitted, Ieva Saulitee, Peter Schmid-Grendelmeierf, Kaspar Schürchg, Kathrin Thormannh, Dagmar Simonh

a Jules-Gonin Eye Hospital, Fondation Asile des Aveugles, Ophthalmology Department, University of Lausanne, Switzerland

b Department of Dermatology and Venereology, Lausanne University Hospital, Lausanne, Switzerland

c Dermatologie am Rhein, Basel, Switzerland

d Department of Dermatology, University Hospital of Geneva, Switzerland

e Clinic of Dermatology and Allergology, Cantonal Hospital St Gallen, Switzerland

f Allergy Unit, Department of Dermatology, University Hospital Zurich, Switzerland

g Department of Ophthalmology, Inselspital, Bern University Hospital, University of Bern, Switzerland; new: Eye Centre Burgdorf, Burgdorf, Switzerland

h Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Switzerland


Atopic dermatitis is a chronic inflammatory skin disease characterised by eczematous skin lesions and intense pruritus. It is often associated with other atopic diseases such as allergic rhinitis and conjunctivitis, bronchial asthma and eosinophilic oesophagitis. Dupilumab is the first biologic approved for the treatment of moderate-to-severe atopic dermatitis in Switzerland. Dupilumab targets the interleukin (IL)-4/IL-13 receptor and thus inhibits the signalling of IL-4 and IL-13, two key mediators of type 2 inflammation, resulting in an improvement of clinical signs and symptoms of atopic dermatitis. Patients with atopic dermatitis present more often with ocular surface diseases (OSDs), such as allergic conjunctivitis, blepharitis and keratitis as well as infectious conjunctivitis and keratoconus compared with the general population. Upon dupilumab therapy, increased rates of ocular surface diseases have been reported in clinical trials. Interestingly, dupilumab-associated (da) OSD is restricted to atopic dermatitis patients and has not been observed in asthma and chronic rhinosinusitis trials. Fortunately, most cases of dupilumab-associated OSD are mild-to-moderate and transient. Thus, ocular surface disease presents a particular adverse event of treatment with dupilumab in dermatology. This article aims at providing a practical guide for physicians, with a special focus on dermatologists, allergists and ophthalmologists in Switzerland, to the diagnosis and management of dupilumab-associated OSD in atopic dermatitis patients.

For this purpose, an expert group of dermatologists and ophthalmologists from university and cantonal hospitals in Switzerland reviewed data on ocular surface diseases published in clinical trial and real-life reports of dupilumab therapy, published case reports and case series on the management of dupilumab-associated OSD, as well as recent recommendations provided by experts of national and international boards. Based on the observations of dupilumab-associated OSD and practical experiences in identifying and treating OSD, an algorithm has been developed that is specific to the needs in Switzerland. Considering concomitant ocular diseases and differential diagnoses, the clinical presentation of dupilumab-associated OSD and its response to therapeutic measures, a stepwise approach is recommended. Mild dupilumab-associated OSD can be managed by dermatologists and allergists, whereas patients with moderate-to-severe OSD requiring corticosteroid or calcineurin inhibitor therapy should necessarily be referred to an ophthalmologist. The effects of preventive measures, such as artificial tears, are uncertain. The recommendations provided here should guarantee a prompt and effective treatment of OSD for patients under dupilumab therapy in order to prevent that an otherwise potent therapy has to be ceased because of ocular adverse events.


A Swiss expert group of dermatologists and ophthalmologists with experience in the treatment of ocular surface diseases (OSDs) in patients with atopic dermatitis from university and cantonal hospitals reviewed data in clinical trials and real-life reports on dupilumab therapy, published case reports on the management of OSD, as well as recent national and international recommendations. Based on the observations of dupilumab-associated OSD and practical experience in identifying and treating OSDs, an algorithm has been developed that is specific to the needs in Switzerland. The level of agreement in the development of the algorithm was determined with the consent of seven of the nine experts.

Atopic dermatitis: epidemiology and clinical characteristics

Atopic dermatitis is a chronic inflammatory skin disease presenting with recurrent eczematous lesions, intense pruritus and increased risk of skin infections [1, 2]. It affects approximately 20% of all children up to the age of 6 years and 5% of adults in Western industrialised countries [1]. Because of its chronic disease course, it requires long-term treatment [1]. Atopic dermatitis is based on a genetic predisposition, which affects both the epithelial barrier and a type 2 based immune reaction [3].

Besides affecting the skin, atopic dermatitis is associated with substantial psychosocial distress as well as with other atopic diseases such as bronchial asthma, allergic rhinitis and eosinophilic oesophagitis [4–6].

Ocular surface diseases frequently associated with atopic dermatitis

Patients with atopic dermatitis have an increased risk of different ocular surface diseases with conjunctivitis as the most frequent ocular comorbidity in the atopic dermatitis population (supplementary table S1 in the appendix) [7, 8].

Figure 1

Common ocular surface diseases in atopic dermatitis patients. Stock pictures by istock and shutterstock.

Incidence and differential diagnosis of ocular surface diseases in atopic dermatitis

Ocular surface diseases, such as allergic conjunctivitis, blepharitis and keratitis, are well-known ophthalmic comorbidities in patients with atopic dermatitis, in particular those with severe disease in whom incidence rates of 32.4–55.8% have been reported [9]. For atopic keratoconjunctivitis alone in atopic dermatitis patients, an incidence rate of 25% to 42% is given [10].

Since the clinical signs and symptoms of allergic conjunctivitis are not pathognomonic, it is essential to consider a broad spectrum of differential diagnoses (fig.1). As trigger of OSD, in particular when associated with lid dermatitis, irritant and allergic contact dermatitis have to be ruled out [11].

Red flags for immediate ophthalmological consultation are loss of transparency in the eye, vision loss, discharge and an increase in ocular pressure [12]. Patients wearing contact lenses presenting with red eyes should immediately be referred since they are at high risk of having an infectious keratitis.

Mode of action of dupilumab

Dupilumab, a monoclonal antibody, targets the shared interleukin (IL)-4/IL-13 receptor α-chain and thus blocks the action of IL-13 and IL-4 (fig. 2) [1, 13]. IL-13 in particular has been shown to play a key role in the pathogenesis of atopic dermatitis [1].

Figure 2

The targets of dupilumab in atopic dermatitis skin characterised by a type 2 immune reaction. Illustration: Aldona von Guten (modified from: Simon D, Wollenberg A, Renz H, Simon HU. Atopic Dermatitis: Collegium Internationale Allergologicum (CIA) Update 2019. Int Arch Allergy Immunol. 2019;178(3):207–18 [1], reprinted with permission from S. Karger AG, Basel).

Efficacy and safety of dupilumab

In several clinical trials in patients with moderate-to-severe atopic dermatitis, dupilumab has been shown to exhibit an excellent and well-balanced efficacy and safety profile [14–19]. A 75% improvement of the Eczema Area and Severity Index (EASI) was achieved in 47.7% to 69% of dupilumab-treated patients versus 13.3% to 29.6% of the placebo group after 16 weeks [15, 16, 20]. More detailed information is provided in table S1, in the appendix) [14–19]. The most common adverse events observed were injection site reactions (9.6%), conjunctivitis (>1%, <10%), blepharitis (>1%, <10%) and oral herpes (>1%, <10%) [21].

Dupilumab-associated OSD exclusively affects atopic dermatitis patients

Results from clinical trials

In clinical trials, the diagnosis of conjunctivitis was usually reported by dermatologists and allergists, whereas no specific assessments by ophthalmologists were required for diagnosis. Therefore, a specific categorisation of conjunctivitis is not available and the frequencies reported include all cases of conjunctivitis regardless of their aetiology. The incidence of conjunctivitis was 17.9–22.1% in the dupilumab and 7.9–11.1% in the placebo group after 16 weeks (table S1). Numerical differences between placebo and dupilumab were apparent after about 4–8 weeks [9, 14–19].

In a long-term open-label extension study for patients previously enrolled in phase II and III studies, conjunctivitis was reported in only 10.7%, suggesting that it mainly occurs during the first months of dupilumab therapy and may recover [18]. In most cases, conjunctivitis was mild to moderate [18]. Overall, there were <1% of patients who discontinued dupilumab treatment because of ocular adverse events [9]. Moreover, in a long-term study, the incidence rates of 4.7% and 4.9%, respectively, were similar in both dupilumab and placebo groups at week 36, indicating that dupilumab-associated OSD is transient [9, 14–16].

Higher baseline severity of atopic dermatitis and levels of thymus and activation-regulated chemokine (TARC), total immunoglobulin E and blood eosinophil counts, as well as a history of conjunctivitis were associated with an increased risk to develop a dupilumab-associated OSD [9]. Still, the pathogenesis of dupilumab-associated OSD and the reason why it occurs almost exclusively in atopic dermatitis patients needs to be elucidated.

OSD in clinical trials with dupilumab in other diseases

In atopic diseases other than atopic dermatitis, such as asthma, chronic rhinosinusitis with nasal polyposis or eosinophilic oesophagitis, dupilumab therapy was not associated with an increased risk for conjunctivitis, suggesting that the relatively high rates of conjunctivitis in atopic dermatitis trials may reflect unique effects of dupilumab on the ocular surface of these patients [9, 16, 22–25].

Observations in clinical practice

So far, real-world evidence data on the efficacy and safety of dupilumab in atopic dermatitis patients from the Netherlands, France and Denmark are available [26–28]. Here, conjunctivitis rates of 18.4%, 34.1% and 38.2%, respectively, have been reported (supplementary figure S1 in the appendix) [26–28]. Moreover, both severity of atopic dermatitis and the age of the patients were associated with dupilumab-associated OSD [8]. It appears that dupilumab-associated OSD in real-world evidence with unselected patients probably having more comorbidities, occurs more frequently than in clinical trials [26].

Hypoheses on the pathogenic mechanisms in dupilumab-associated OSD

Various hypotheses have been proposed for mechanisms that drive conjunctivitis in atopic dermatitis patients treated with dupilumab. These include inflammatory and noninfectious processes such as unmasking preexisting subclinical atopic or allergic inflammatory processes [8], quantitative and qualitative tear production failures [8], the IL-4 mediated lipogenesis by Demodex mite colonisation of the Meibomian glands, an increased systemic bioavailability of free IL-4 and IL-13 causing inflammatory symptoms, a decrease of IL-13 mediated mucus production and an IL-13-related scarcity of conjunctival goblet cells [8, 29, 30].

Management of dupilumab-associated OSD in atopic dermatitis patients

Based on the literature and our own experiences we developed recommendations on how to manage dupilumab-associated OSD (fig. 3):

  • Depending on the clinical presentation of dupilumab-associated OSD and its response to therapeutic measures, a stepwise approach is recommended.
  • Before initiating dupilumab treatment: If a patient presents with ocular disorders that cannot be managed by a dermatologist or allergist, an ophthalmological examination should be planned to diagnose preexisting eye disease.
  • Due to the lack of clinical experience and study data, recommendations for prophylactic treatment cannot be provided.
  • Step 1: measures taken by dermatologists and allergists: If clinical signs and symptoms of dupilumab-associated OSD such as hyperaemia, tearing, dry eye, sand corn feeling and pruritus appear, warm compresses and artificial tears and ointments can be used as first line.
  • If a seasonal or perennial allergic conjunctivitis is present, topical or systemic antihistamines are recommended.
  • Single dose units should always be preferred to prevent adverse events (irritation or allergic reaction) caused by preservatives.
  • If symptoms are not relieved within one to two weeks, the topical application of calcineurin inhibitors on the eyelids or diclofenac eye drops can be considered. Physicians should be aware that these substances may cause burning and irritation, respectively, in dry eye.
  • Red flags for an urgent ophthalmologic consultation are: vision loss, pain, purulent discharge, corneal involvement and conjunctival scarring [12]. Patients wearing contact lenses should rapidly be referred in the presence of ocular symptoms [31].
  • Step 2: measures taken by ophthalmologists: If clinical signs and symptoms of OSD do not respond to the therapeutic measures described in Step 1 within 1 to 2 weeks, the patient has to be referred to an ophthalmologist. As topical corticosteroids can cause increased intraocular pressure in 20% of patients even after only 2 weeks, intraocular pressure has to be measured prior to and during use of steroids. Topical corticosteroids with low penetration rate into the eye such as fluorometholone should be preferred.
  • If OSD does not improve despite topical corticosteroids within 2 to 3 weeks, topical ciclosporin (ciclosporin 1 mg/ml eye drops), emulsion or lifitegrast, an antagonist of the integrin lymphocyte function-associated antigen 1/LFA-1 (lifitegrast 50 mg/ml eye drops) should be considered. Of note, for reimbursement of ciclosporin and lifitegrast eye drops, an application for cost assumption by the patient’s health insurance company may be required.
Figure 3

Algorithm for the management of dupilumab-associated ocular surface diseases in atopic dermatitis patients developed by a Swiss expert group of dermatologists and ophthalmologists.


In the spectrum of OSD, dupilumab-associated OSD presents a novel subgroup that poses a challenge for all, dermatologists, allergists and ophthalmologists. Specific challenges are

1. For the dermatologist and allergist:

(a) to diagnose dupilumab-associated OSD and distinguish it from other OSDs

(b) to evaluate the severity of OSD

(c) to manage mild forms of dupilumab-associated OSD

(d) to interact with ophthalmologists

(e) to be aware of red flags on severe forms requiring urgent ophthalmological intervention

2. For the ophthalmologist:

(a) To recognise dupilumab-associated OSD as a novel adverse effect of atopic dermatitis therapy

(b) To interact with dermatologists

(c) To manage severe forms of dupilumab-associated OSD requiring immunosuppressive or immunomodulating therapy

As result of our expert group meeting, we provide a summary of current knowledge on dupilumab-associated OSD and its management in daily practice. The discussion on and our clinical experience with dupilumab-associated OSD clearly demonstrate how important the collaboration between dermatologists, allergists and ophthalmologists is in order to achieve best therapeutic results for atopic dermatitis patients. We are aware that, as we will learn more on the pathogenesis of dupilumab-associated OSD, on how to identify patients at risk and therapeutic approaches, we will probably have to adapt and revise our recommendations in the near future.

Approval for dupilumab in Switzerlan

Indication: Dupilumab (Duxipent®) was approved in Switzerland in April 2019 and is indicated for the treatment of moderate-to-severe atopic dermatitis in adult patients and adolescents aged 12 years and older when treatment with prescription topical medications does not provide adequate disease control or is not recommended. Dupixent can be used with or without topical corticosteroids [21].

Administration: Duxipent® (dupilumab) is administered in an initial dose of 600 mg by subcutaneous injection (two injections of 300 mg each), followed by a dose of 300 mg by subcutaneous injection every 2 weeks for the treatment of adult patients (from the age of 18) with severe atopic dermatitis (Investigator Global Assessment [IGA] 4, on an IGA scale of 0–4, or scoring atopic dermatitis (SCORAD) score >50 or EASI ≥21.1), if patients have had an inadequate response to intensified local treatment with prescription topical therapies (topical corticoids and/or calcineurin inhibitors) and phototherapy (if available and indicated) and systemic treatment with a conventional immunosuppressive agent (excluding systemic corticoids) for at least 1 month, or where these therapies are contraindicated or have had to be discontinued because of clinically relevant adverse events. Duxipent® is not reimbursed in combination with other systemic drugs for the treatment of atopic dermatitis. If after 16 weeks of treatment with Duxipent® no therapeutic success has been achieved, i.e., an IGA reduction of ≥2 points compared with the initial value or a ≥50% improvement of the EASI score compared with the initial value or a ≥50% improvement of the SCORAD score compared with the initial value, treatment must be discontinued. The treatment costs are reimbursed after prior consultation with a medical examiner. The diagnosis, prescription of Duxipent® and follow-up may only be made by a specialist in dermatology and venereology or a specialist in allergology and clinical immunology. After 52 weeks of uninterrupted therapy, the health insurer must again approve the costs after prior consultation with the medical advisor [25].

Financial disclosure

The contents of this practice guide were developed by Swiss experts in the therapy of atopic dermatitis and eye diseases on the occasion of an expert meeting. The expert meeting was supported by Sanofi Genzyme.

Pontential conflicts of interest

Y. Guex-Crosier: none; J. Di Lucca has served as investigator for Roche Pharma and Eli Lilly, and advisor for Sanofi Genzyme; P. Häusermann has served as a speaker, and/or advisor for AbbVie, Almirall, Amgen, Celgene, Eli Lilly, Galderma, Janssen, LEO Pharma, Novartis, Sanofi Genzyme; E. Laffitte has served as an investigator, speaker, and/or advisor from Abbvie, Amgen, Celgene, Eli Lilly, Galderma, Janssen, LEO Pharma, Novartis, Merck Sharp & Dohme, Sanofi Genzyme and Pfizer; L. Saulite: none; P. Schmid-Grendelmeier has received honoraria for advisory boards and as speaker from AbbVie, LEO Pharma, GlaxoSmithKline, Novartis, Pfizer, Roche Pharma and Sanofi Genzyme; K. Schürch: none; K. Thormann: none; D. Simon reports serving as an investigator and/or consultant for AbbVie, Astra Zeneca, Galderma, Eli Lilly, Pfizer, Roche Pharma and Sanofi Genzyme. 

The authors have no conflicts of interest that are directly relevant to the content of this article.


Prof. Dagmar Simon, MD

Department of Dermatology

Inselspital, Bern University Hospital

University of Bern

Freiburgstrasse 34

CH-3010 Bern



1. Simon D, Wollenberg A, Renz H, Simon HU. Atopic Dermatitis: Collegium Internationale Allergologicum (CIA) Update 2019. Int Arch Allergy Immunol. 2019;178(3):207–18. PubMed 1423-0097

2. Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016 Mar;387(10023):1109–22. PubMed 1474-547X

3. Wohlrab J, Wollenberg A, Reimann H, Pleyer U, Werfel T. Interdisziplinäre Handlungsempfehlung bei Dupilumab-assoziierten entzündlichen Augenerkrankungen [Interdisciplinary recommendations for action in dupilumab-related inflammatory eye diseases]. Hautarzt. 2019 Jan;70(1):64–7. PubMed 1432-1173

4. Eichenfield LF, Tom WL, Chamlin SL, Feldman SR, Hanifin JM, Simpson EL Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014 Feb;70(2):338–51. PubMed 1097-6787

5. Silverberg JI, Nelson DB, Yosipovitch G. Addressing treatment challenges in atopic dermatitis with novel topical therapies. J Dermatolog Treat. 2016 Nov;27(6):568–76. PubMed 1471-1753

6. Bieber T. Atopic dermatitis. N Engl J Med. 2008 Apr;358(14):1483–94. PubMed 1533-4406

7. Thyssen JP, Toft PB, Halling-Overgaard AS, Gislason GH, Skov L, Egeberg A. Incidence, prevalence, and risk of selected ocular disease in adults with atopic dermatitis. J Am Acad Dermatol. 2017 Aug;77(2):280–286.e1. PubMed 1097-6787

8. Wohlrab J, Werfel T, Wollenberg A. Pathomechanism of dupilumab-associated inflammatory eye symptoms. J Eur Acad Dermatol Venereol. 2019 Nov;33(11):e435–6. PubMed 1468-3083

9. Akinlade B, Guttman-Yassky E, de Bruin-Weller M, Simpson EL, Blauvelt A, Cork MJ Conjunctivitis in dupilumab clinical trials. Br J Dermatol. 2019 Sep;181(3):459–73. PubMed 1365-2133

10. Bielory L. Allergic and immunologic disorders of the eye. Part II: ocular allergy. J Allergy Clin Immunol. 2000 Dec;106(6):1019–32. PubMed 0091-6749

11. Raffi J, Suresh R, Fishman H, Botto N, Murase JE. Investigating the role of allergic contact dermatitis in residual ocular surface disease on dupilumab (ROSDD). Int J Womens Dermatol. 2019 Nov;5(5):308–13. PubMed 2352-6475

12. Cronau H, Kankanala RR, Mauger T. Diagnosis and management of red eye in primary care. Am Fam Physician. 2010 Jan;81(2):137–44. PubMed 1532-0650

13. Brunner PM, Guttman-Yassky E, Leung DY. The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies. J Allergy Clin Immunol. 2017 Apr;139(4 4S):S65–76. PubMed 1097-6825

14. Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, SOLO 1 and SOLO 2 Investigators. SOLO 1 and SOLO 2 Investigators. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016 Dec;375(24):2335–48. PubMed 1533-4406

15. Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017 Jun;389(10086):2287–303. PubMed 1474-547X

16. de Bruin-Weller M, Thaçi D, Smith CH, Reich K, Cork MJ, Radin A Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ). Br J Dermatol. 2018 May;178(5):1083–101. PubMed 1365-2133

17. Worm M, Simpson EL, Thaçi D, Bissonnette R, Lacour JP, Beissert S Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis: A Randomized Clinical Trial. JAMA Dermatol. 2020 Feb;156(2):131–43. PubMed 2168-6084

18. Deleuran M, Thaçi D, Beck LA, de Bruin-Weller M, Blauvelt A, Forman S Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study. J Am Acad Dermatol. 2020 Feb;82(2):377–88. PubMed 1097-6787

19. Beck LA, Thaçi D, Deleuran M, Blauvelt A, Bissonnette R, de Bruin-Weller M Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis. Am J Clin Dermatol. 2020 Aug;21(4):567–77. PubMed 1179-1888

20. Thaçi D, L Simpson E, Deleuran M, Kataoka Y, Chen Z, Gadkari A Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2). J Dermatol Sci. 2019 May;94(2):266–75. PubMed 0923-1811

21. Duxipent® (Dupilumab), product information for healthcare professionals, status of information: September 2020,, last accessed: 07 January 2021.

22. Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. N Engl J Med. 2018 Jun;378(26):2486–96. PubMed 1533-4406

23. Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N, Lee SE Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019 Nov;394(10209):1638–50. PubMed 1474-547X

24. Hirano I, Dellon ES, Hamilton JD, Collins MH, Peterson K, Chehade M Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis. Gastroenterology. 2020 Jan;158(1):111–122.e10. PubMed 1528-0012

25. Ariëns LF, van der Schaft J, Bakker DS, Balak D, Romeijn ML, Kouwenhoven T Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: first clinical and biomarker results from the BioDay registry. Allergy. 2020 Jan;75(1):116–26. PubMed 1398-9995

26. Faiz S, Giovannelli J, Podevin C, Jachiet M, Bouaziz JD, Reguiai Z, Groupe de Recherche sur l’Eczéma aTopique (GREAT), France. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort. J Am Acad Dermatol. 2019 Jul;81(1):143–51. PubMed 1097-6787

27. Olesen CM, Holm JG, Nørreslet LB, Serup JV, Thomsen SF, Agner T. Treatment of atopic dermatitis with dupilumab: experience from a tertiary referral centre. J Eur Acad Dermatol Venereol. 2019 Aug;33(8):1562–8. PubMed 1468-3083

28. Bakker DS, Ariens LF, van Luijk C, van der Schaft J, Thijs JL, Schuttelaar ML Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis. Br J Dermatol. 2019 May;180(5):1248–9. PubMed 1365-2133

29. Jun I, Kim BR, Park SY, Lee H, Kim J, Kim EK Interleukin-4 stimulates lipogenesis in meibocytes by activating the STAT6/PPARγ signaling pathway. Ocul Surf. 2020 Oct;18(4):575–82. PubMed 1937-5913

30. Becmeur PH, Abry F, Bourcier T, Meyer N, Sauer A, « the French Study Group for Contact Lens-Related Microbial Keratitis ». Facteurs de risque de kératites infectieuses chez les porteurs de lentilles de contact, une étude cas-témoins [Risk factors for contact lens-related microbial keratitis: A multicenter case-control study]. J Fr Ophtalmol. 2017 Mar;40(3):224–31. PubMed 1773-0597

31. Duxipent® (dupilumab), Federal Office of Public Health (FOPH), Spezialitätenliste. Available at: [last accessed: 2021 January 07].

Appendix: Supplementary data

Table S1

Efficacy and safety of dupilumab in phase III clinical trials [14–19]. (Disclaimer: The only approved dosing regimen of dupilumab for the treatment of moderate-to-severe atopic dermatitis is every 2 weeks.)

SOLO 1, 16 weeks [14]Dupilumab 300 mg, q2w (N = 224)Placebo (N = 224)
 EfficacyEASI 75  115 (51%)33 (15%)
  IGA Score 0 or 1  85 (38%)23 (10%)
 Safety, dupilumab 300 mg, q2wAEs: injection-site reaction (8%), exacerbation of AD (13%), headache (9%), allergic conjunctivitis (5%), nasopharyngitis (10%), upper respiratory tract infection (3%), conjunctivitis (5%), any herpes viral infection (7%), adjudicated skin infection (6%), non-skin infection (30%)  AEs (≥1), 166 (73%)AEs (≥1), 144 (65%)
 OSDConjunctivits  11 (5%)2 (1%)
  Conjunctivitis allergic  12 (5%)2 (1%)
SOLO 2, 16 weeks [14]Dupilumab 300 mg, q2w (N = 233)Placebo (N = 236)
 EfficacyEASI 75  103 (44%)28 (12%)
  IGA Score 0 or 1  84 (36%)20 (8%)
 Safety, dupilumab 300 mg, q2wAEs: injection-site reactions (14%), exacerbation of AD (14%), headache (8%), allergic conjunctivitis (1%), nasopharyngitis (20%), upper respiratory tract infection (3%), conjunctivitis (4%), any herpes viral infection (4%), adjudicated skin infection (6%), non-skin infection (25%)  AEs (≥1), 154 (65%)AEs (≥1), 168 (72%)
 OSDConjunctivitis  9 (4%)1 (< 1%)
  Conjunctivitis allergic  2 (1%)2 (1%)
LIBERTY AD CHRONOS,16 weeks, 52 weeks [15]Dupilumab 300 mg, q2w + TCS (N = 106), week 16Placebo, qw + TCS (N = 315), week 16Dupilumab 300 mg, q2w + TCS (N = 89), week 52Placebo, qw + TCS (N = 264), week 52
 EfficacyEASI 7573 (69%)73 (23%)58 (65%)57 (22%)
  IGA Score 0 or 141 (39%)39 (12%)32 (36%)33 (13%)
 Safety, dupilumab 300 mg, q2w + TCS, 52 week-periodAEs: nasopharyngitis (23%), upper respiratory tract infection (10%), sinusitits (2%), influenza (4%), eye disorders (31%), conjunctivitis (14%), atopic dermatitis (18%), injection site reaction (15%), asthma (5%), headache (5%), non-herpetic skin infections (11%), any herpes infections (7%)  AEs ≥1 97 (88%)AEs ≥1 266 (84%)
 OSD, 52 week-periodConjunctivitis (conjunctivitis allergic, conjunctivitis bacterial, atopic keratoconjunctivitis, and conjunctivitis)15 (14%)25 (8%)  
LIBERTY AD CAFÉ, 16 weeks [16]Dupilumab 300 mg, q2w + TCS (N = 107)Placebo + TCS (N = 108)
 EfficacyEASI 75  67 (62.6%)32 (29.6%)
  IGA  43 (40.2%)15 (13.9%)
 Safety, dupilumab 300 mg, q2w + TCSAEs: nasopharyngitis (20.6%), conjunctivitis (11.2%), oral herpes (2.8%), gastroenteritis (1.9%), upper respiratory tract infection (0.9%), pharyngitis (0.9%), herpes simplex (0.9%), atopic dermatitis (7.5%), allergic conjunctivitis (15%), lacrimation increased (0.9%), fatigue (3.7%), injection site reaction (0.9%), injection site erythema (0.9%), headache (9.3%), rhinitis allergic (6.5%), cough (3.7%), oropharyngeal pain (2.8%), asthma (0.9%), diarrhea (2.8%), back pain (0.9%), vascular disorders (3.7%), hypertension (0.9%), blood and lymphatic system disorders 3.7%, lymphadenopathy (1.9%), skin infections, excl. herpetic infections (1.9%)  AEs ≥1, 77 (72%)AEs ≥1, 75 (69.4%)
 OSD: Treat-ment-emergent conjunctivitisConjunctivitis  12 (11.2%)3 (2.8%)
  Conjunctivitis allergic  16 (15%)7 (6.5%)
  Adenovirus conjunctivitis  1 (0.9%)0.00%
  Conjunctivitis bacterial  1 (0.9%)2 (1.9%)
  Conjunctivitis viral  1 (0.9%)1 (0.9%)
SOLO-CONTINUE, 36 weeks [17]Dupilumab 300 mg, q8w (N = 84)Dupilumab 300 mg, q4w (N = 86)Dupilumab 300 mg, qw or q2w (N = 169)Placebo (N = 83)
No./Tot No.(%)EfficacyEASI 7545/82 (54.9%)49/84 (58.3%)116/162 (71.6%)24/79 (30.4%)
No./Tot No.(%) IGA score 0 or 121/64 (32.8%)29/66 (43.9%)68/126 (54%)9/63 (14.3%)
 Safety, dupilumab 300 mg, wk or q2wAEs: dermatitis atopic (20.4%), nasopharyngitis (19.2%), upper respiratory tract infection (7.8%), headache (4.8%), herpes simplex virus infection (4.2%), asthma (2.4%), back pain (3.6%), oral herpes infection (1.8%), influenza (2.4%), bronchitis (1.8%), urticaria (3.0%), arthralgia (3.0%), pharyngitis (1.8%), diarrhea (2.4%), pruritus (1.8%), sinusitis (3.6%), blood creatin phophosphokinase increased (0.6%), cough (2.4%), insomnia (2.4%), nasal congestion (2.4%), contact dermatitis (0.6%), gastroenteritis (1.8%), ligament sprain (1.2%), toothache (2.4%), contusion (0.6%), hypertension (1.2%), proteinuria (0.6%), rhinitis (0.6%), tonsillitis (0.6%), urinary tract infection (1.2%), viral infection (1.2%), ophthalmic herpes infection (0.6%), musculoskeletal pain (0.6%), vulvovaginal candidiasis (1.2%), fall (0.6%), eye disorders with preferred term conjunctivitis (5.4%), non-herpetic skin infections (2.4%), injection-site reaction (10.8%)AEs ≥1, 63 (75%)AEs ≥1, 64 (73.6%)AEs ≥1, 118 (70.7%)AEs ≥1, 67 (81.7%)
 OSDConjunctivitis: conjunctivitis, conjunctivitis bacterial, conjunctivitis viral, conjunctivitis allergic, and atopic keratoconjunctivitis3 (3.6%)4 (4.6%)9 (5.4%)4 (4.9%)
OPEN LABEL EXTENSION, week 52 [8], 76 [18] and week 148 [19]Dupilumab 300 mg, qw (N = 428), week 52Dupilumab 300 mg, qw (N = 284), week 76Dupilumab 300 mg, qw (N = 347), week 148
n/subgroup (%)EfficacyEASI 75 346/398 (86.9%)220/249 (88.4%)56/58 (96.6%)
n/subgroup (%) IGA score 0 or 1 221/398 (55.5%)144/249 (57.8%)43/58 (74.1%)
 Safety, 76 week-periodAEs: nasopharyngitis (20%), upper respiratory tract infection (9.5%), dermatitis atopic (8.2%), headache 7.1%), oral herpes (4.3%), blood creatin phophosphokinase increased (3.6%), bronchitis (3.2%), diarrhea (2.7%), back pain (2.7%), viral upper respiratory tract infection (2.5%), cough (2.3%), influenza (2.1%), conjunctivitis (10.7%), injection site reaction (10.1%)  AEs ≥1, 1054 (70.7%)AEs ≥1, 2264 (84.6%)
Figure S1

Real world evidence data of dupilumab collected in country-specific registries [26–28].

Verpassen Sie keinen Artikel!